Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with Unresectable Advanced Melanoma By Ogkologos - September 10, 2025 430 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LEAP-003 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR FDA Expands Early Breast Cancer Indication for Abemaciclib with Endocrine Therapy March 16, 2023 The R50 Research Specialist Award: Ensuring a Stable Cancer Research Workforce September 27, 2018 National Study Examines Genetic Testing to Inform Follow-up Care for Cancer... May 7, 2026 Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients... May 7, 2026 Load more HOT NEWS Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with... Cancer in My Community: Overcoming Inequities in Care in Argentina Neoadjuvant Histotype-Tailored Treatment with Trabectedin Not Inferior to Standard Chemotherapy with... Coronavirus reports – Part 6 “The kids being home all the...
